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Abstract
BACKGROUND: Metaplastic breast carcinoma (MBC) is a rare disease with incidence of less than 1%. MBC present with a larger tumor size, 
less number of nodes involved, mostly undifferentiated triple negative tumors. We aimed to determine progression‑free and overall survival and 
reported hospital‑based incidence of MBC. 
MATERIAL AND METHODS: A retrospective closed Cohort study elicited data of 42 patients with MBC from January 2008 to December 2013; 
followed till August 2016. Kaplan‑Meier method was applied to compute overall and progression‑free survival analysis. Cox Proportional hazard 
ratios were computed to assess associations between survival and independent variables. 
RESULTS: Hospital‑based incidence of MBC was 1.92% (42/2187), 95% CI [1.41‑2.56]. The median age at tumor diagnosis was 54 years (range, 
25–81 years). Thirty‑nine (92.9%) patients had Grade III tumor. The most common histopathology was squamous (69%). The median tumor size 
was 4.5 cm (range, 0.8–17 cm). Nineteen (45.2%) patients had nodal involvement at diagnosis. Four patients (9.5%) had metastatic disease 
at presentation. Hormone receptors were positive in 19 (45.2%) patients. Her‑2 neu receptor was positive in 9 (19%) patients. Sixteen (38.1%) 
patients had triple negative disease. Neoadjuvant and adjuvant chemotherapy was received by 10 (31.25%) and 19 (45.2%) patients respectively. 
Both median progression‑free and overall survival was 38 months. 
CONCLUSION: Five‑year progression‑free and overall survival was 79.5% and 76.3%, respectively. We report better survival outcomes when 
compared to series described earlier despite our patient population presenting mostly with high grade, large tumors, and half of them exhibiting 
nodal and hormonal involvement.
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Introduction
Metaplastic breast carcinoma (MBC) is a rare disease. Its 
incidence is said to be less than 1% amongst all breast 
cancer sub-types.[1] In a study from India, its incidence 
was reported as 0.9%.[2] They are a heterogeneous group 
of diseases having epithelial and mesenchymal components. 
Two to three different components may occur within the 
tumor at the same time.[3-9] According to Wargotz et al. 
there are five variants of MBC which include matrix 
producing carcinomas, squamous cell carcinoma, spindle 
cell carcinoma, carcinosarcoma, and metaplastic carcinoma 
with osteoclastic giant cells.[3-8] Cumulative five-year survival 
rates of various subtypes ranges from 49% to 68%.
[3-7] In comparison to invasive ductal carcinomas (IDC), 
MBC present with a larger tumor size, less number of 
nodes involved, mostly undifferentiated tumors, which are 
usually triple negative.[1,10,11] When compared with IDC, 
patients with MBC have a shorter overall survival.[12,13] In 
a study by Nelson et al. five-year disease specific survival 
was 78% in MBC as compared to 93% in those with 
IDC (p < 0.0001).[14] There is no optimum treatment 
approach for management of MBC. Its management has 
been essentially similar to that of IDC.[15]
In this study, we reviewed a single center attempt to report 
outcome in terms of overall and progression-free survival 
of MBC patients. We analyzed several parameters such as 
menopausal status, tumor grade, stage, hormonal receptor, 
and Her 2 Neu status. This study reports the hospital-based 
incidence rate/proportion of MBC among all breast cancer 
subtypes. There was a lack of scientific literature from the 
developing countries regarding treatment options of MBC. 
Therefore, the study results may help in meeting the void.
Material and Methods
Overview of study
A retrospective close cohort study was designed to collect 
data. Data in this study were mainly collected from the 
Aga Khan University Hospital cancer registry and Health 
Information and Management System (HIMS) from 
January 2008 till December 2013. This system established 
in 2009, is managed by the HIMS to identify all new cases. 
According to the Cancer Registry Regulations, this system 
identifies cancer in patients who report to our hospital 
for medical advice from all over Pakistan. The Aga Khan 
University Hospital (AKUH) is one of the main private 
cancer hospitals in the region. The follow up of patients 
with MBC was prospectively done until August 2016 
regarding disease progression and survival.
Study population
All cases in the AKUH cancer registry and management 
system were identified by the coding system of the 
International Classification of Diseases for Oncology, 
3rd Revision (ICD-03), from the World Health 
Organization.[16] In order to confirm the diagnosis of MBC 
and examine the changes on coding, we retrospectively 
collected and checked records of diagnosis and pathological 
reports of these cases. A review of the biopsy specimen was 
done by an experienced pathologist in order to confirm 
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the diagnosis of MBC. A total of 42 patients who were 
diagnosed from August 2008 to December 2013 were 
recruited to calculate the progression-free survival and 
overall survival in this study. Non-probability purposive 
sampling methodology was employed to enroll patients for 
the study from the Health Information and Management 
System (HIMS). Patients aged 16 and above diagnosed with 
MBC and treated at the hospital were recruited. Patients 
were excluded if they were treated at another center, did 
not have a histologically confirmed diagnosis or sufficient 
staging information. Patients with bilateral disease were also 
excluded.
Exposure variables under study
The following variables were recorded at baseline for 
each patient including age, menopausal status, tumor 
grade, histological subtype, tumor size, nodal status, and 
metastatic involvement at presentation. Hormone receptor 
status including estrogen receptor (ER), progesterone 
receptor (PR) and Her-2 positivity were also documented. 
Type of surgery, chemotherapy received, be it neo-adjuvant, 
adjuvant or palliative, types of radiation received were also 
recorded. Development of locally recurrent disease and sites 
of distant metastasis were documented.
Estrogen receptor (ER), and progesterone receptor (PR) 
was defined according to Allred scoring as positive when 
the sum of proportion and intensity was two and above.[17] 
Her-2 positivity was defined as more than 10% strong 
complete membrane staining or positive with fluorescent 
in situ hybridization technique (FISH).[18]
Outcome
We examined two outcomes in terms of progression-free 
survival and overall survival. Progression-free survival (PFS) 
was calculated from the date of diagnosis until disease 
progression, death for any reason or the date of last 
contact. Overall survival (OS) was calculated from the date 
of diagnosis until death for any reason or the date of last 
contact. The follow up was prospectively done; PFS and 
OS were recorded by reviewing the charts and documenting 
last clinic visit. Hospital-based incidence rate/proportion of 
MBC was also computed. This was calculated by taking into 
account the number of newly diagnosed MBC patients and 
dividing them with all breast cancer subtypes that reported 
to the hospital from 2008 till 2013.
Ethics approval
The study protocol was initially accepted from the Ethical 
Review Committee of Aga Khan University Hospital, 
Karachi, Pakistan, with ERC #3026-Med-ERC-14.
Statistical analysis
Data were entered into IBM SPSS Statistics for Windows, 
Version 19.0. Armonk, NY: IBM Corp. software and 
were transported and analyzed on STATA. Hospital-based 
incidence rate/proportion of MBC was computed. Mean and 
standard deviation was computed for continuous variables 
and proportions were reported for categorical variables. 
The purpose of the analysis was to report progression-free 
survival and overall survival. Survival analysis was applied in 
order to determine progression-free survival rate and overall 
survival rate of patients with MBC. A P value of less than 
0.05 was considered as statistically significant. Log rank 
test and Breslow test were assessed to check Proportional 
Hazard assumptions, P value 0.049 and 0.061, respectively. 
Therefore, the assumptions of survival analysis were met. 
Cox Proportional hazard ratios were computed to assess 
associations between survival and independent variables. 
The independent variables were menopausal status, tumor 
size, tumor grade, ER, PR, and Her 2 neu status, nodal 
involvement and disease stage. By applying non-parametric 
Kaplan-Meier survival curve technique, we estimated the 
PFS and OS rate.
Results
A total of 42 women were included from January 2008 
until December 2013 in the study. They were followed up 
till August 2016. Their mean ± SD age at diagnosis was 
55.52 ± 12.473 years. The median age at tumor diagnosis 
was 54 years (range, 25–81 years). The mean ± SD follow 
up period was 39.77 ± 24.19 months. Their median 
follow-up period was 34 months (range, 0–94 months). 
There were 3 censored cases and 9 deaths. The data were 
censored under circumstances of being diagnosed at AKUH, 
but not seeking treatment from our center. One patient died 
because of myocardial infarction while on surveillance; seven 
died due to disease progression and one due to unknown 
cause. At data cut off, thirty patients were alive, three with 
disease and twenty-seven without disease.
Hospital-based incidence rate of MBC was 
1.92% (42/2187), 95% CI [1.41-2.56].
Patient characteristics
Thirteen patients (31%) were premenopausal, the remaining 
postmenopausal. Nineteen patients (45.2%) were reported as 
hormone receptor positive and nine patients (19%) as Her 
2-neu positive disease. Sixteen (38.1%) patients presented with 
triple negative disease. Squamous cell was the most common 
histology found in twenty-nine patients (69%). The mean 
tumor size was 4.7 cm ± 3.210 SD, (range, 0.8–17 cm); 
90% of patients presented with tumor size > 2 cm. In 
this study, 19 (45.2%) patients presented with nodal 
involvement at diagnosis. Even though majority (57.1%) 
of the patients were diagnosed with stage two diseases, 
most (92.9%) of them existed as Grade III tumor patients. 
Four patients (9.5%) presented with metastatic disease at 
presentation, lung being the most common site involved, 
followed by bone and liver. All four of them had squamous 
histology. The baseline characteristics are given in Table 1.
Curative treatment
Neoadjuvant chemotherapy was received by 10 patients 
(31.25%). Among these 8 (80%) were of squamous 
histology. Anthracycline- and taxane-based chemotherapy 
was the most common (70%) regimen used in this setting. 
Among these five (50%) had a complete response.
Twenty-seven (64.3%) patients underwent modified radical 
mastectomy, which was the most common surgery. Four 
(9.5%) patients underwent simple mastectomy and sentinel 
lymph node biopsy (+/- axillary lymph node dissection) and 
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8 (19%) underwent lumpectomy and sentinel lymph node 
biopsy (+/- axillary lymph node dissection).
Nineteen patients (45.2%) received adjuvant chemotherapy 
among which 16 (84.2%) were of squamous histology. 
Anthracycline- and taxane-based chemotherapy was again the 
most common (57.9%) regimen used.
Twenty-eight (66.6%) patients received adjuvant radiation 
out of which 16 (38.1%) received radiation to the chest 
wall and axilla.
Fourteen (33.33%) patients received adjuvant hormonal 
therapy among whom 9 (64.29%) received anastrozole and 
5 (35.71%) received tamoxifen.
The details of treatment in the curative setting are given in 
Table 2.
Palliative treatment
At a median follow-up of 34 months (range, 0–94 months), 
metastatic disease was seen in 4 (9.52%) [4/42] patients 
with lung being the most common site followed by bone 
and liver. Out of them, 1 died due to disease and 3 were 
lost to follow up. Progressive disease was observed in 
9 (24.32%) [9/37] patients. Out of them, 6 died due to 
disease, 2 were lost to follow up, and 1 was alive at data 
cutoff. Among the patients with progressive disease, lung 
was the most common site followed by bone. Palliative 
treatment modalities and survival outcomes are given in 
Table 3.
Most of the patients with progressive disease had hormone 
receptor negative disease (77.7%). Three patients received 
hormonal treatment in the palliative setting.
Table 1: Baseline characteristics of patients with 
Metaplastic breast cancer patients
Variable Number of patients Percentage
Histological subtype 42
Squamous 29 69
Spindle 4 9.5
Carcinosarcoma 3 7.1
Spindle cell and squamous 2 4.8
Spindle cell and chondroid 1 2.4
Squamous and chondromyxoid 1 2.4
Subtype not specified 2 4.8
Tumor size
T1 3 7.1
T2 28 66.7
T3 8 19
T4 3 7.1
Nodal status
N0 23 54.8
N1 12 28.6
N2 6 14.3
N3 1 2.4
Stage
Stage I 3 7.1
Stage II 24 57.1
Stage III 10 23.8
Stage IV 5 11.9
ER receptor*
Positive 18 42.9
Negative 23 54.8
Unknown 1 2.4
PR receptor ~
Positive 14 33.3
Negative 27 64.3
Unknown 1 2.4
Her-2 neu receptor
Positive 9 19
Negative 31 73.8
Unknown 3 7.2
Tumor grade
Grade I 0 0
Grade II 2 4.8
Grade III 39 92.9
Unknown 1 2.4
*ER=Estrogen Receptor,  ~PR=Progesterone Receptor
Table 2: Details of treatment in the curative setting
Variable Number of patients (%)
Neoadjuvant chemotherapy (NACT)
Received 10 (23.8)
Not received 32 (76.2)
Chemotherapy regimen
Anthracycline based 2 (20)
Taxane based 1 (10)
Anthracycline and taxane based 7 (70)
Response to NACT
Complete response (CR) 5 (50)
Partial response (PR) 2 (20)
Stable disease (SD) 2 (20)
Progressive disease (PD) 1 (10)
NACT response 
Responsive (CR + PR) 7 (70)
Unresponsive (SD + PD) 3 (30)
Type of surgery
MRM* 27 (64.3)
SM+SLNB/ALND§ 4 (9.5)
BCS+SLNB/ALND ~ 8 (19.0)
Adjuvant Chemotherapy
Received 19 (45.2)
Not received 23 (54.8)
Chemotherapy regimen
Anthracycline based 4 (21.0)
Taxane based 1 (5.3)
Anthracycline and taxane based 11 (57.9)
TC¤ 3 (15.8)
Radiation
Received 28 (66.6)
Not received 14 (33.3)
Hormone treatment
Received 17 (40.5)
Not received 25 (59.5)
*MRM=Modified Radical Mastectomy, § SM+SLNB/ALND=Simple Mastectomy 
and Sentinal Lymph Node Biopsy/Axillary Lymph Node Dissection, ~BCS + 
SLNB/ALND=Breast Conservation Surgery and Sentinal Lymph Node Biopsy/
Axillary Lymph Node Dissection, ¤TC=Taxotere and Cyclophosphamide
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Survival analysis
By applying non-parametric Kaplan-Meier survival curve 
technique, we estimated the five-year PFS rate as 79.5% and 
five year OS rate as 76.3% [Figure 1a and b]. The median 
progression-free survival (PFS) and overall survival (OS) was 
38 months (range, 2–94 months) and 38 months (range, 
4–94 months), respectively. The censored patients were 
excluded from the survival analysis. The overall survival 
based on independent variables is given in Table 4.
The two primary endpoints were PFS and OS among 
patients diagnosed as MBC. Factors associated with better 
progression-free and overall survival were tumor grade and 
menopausal status. When stratified based on Her-2 neu status, 
tumor size, nodal size, tumor stage, or progesterone receptor 
status, neither of these factors were associated with any 
improvement in progression-free or overall survival. Adjusted 
analysis of MBC patient’s survival is given in Table 5.
Discussion
MBC is a rare and heterogeneous group of diseases.[1,12,19] 
In our study it accounted for 1.92% (42/2187) of all 
invasive breast cancers. The median age at presentation 
varies between 45 to 61 years.[1,12,13,19,20] Our study reports 
a median age of 55.5 years, which is in concordance with 
published literature. There is a variability among the median 
tumor size ranging from 3.4-5.7 cm.[12,19,21] The median 
tumor size in our study was 4.5 cm supporting international 
data of these tumors presenting with a large tumor size. 
It is usually associated with negative nodal involvement 
with studies reporting between 4.4 to 35% lymph node 
metastasis.[12,22,23] This is in contrast to our series in which 
53.1% patients had lymph nodes involved. However, in a 
similar Turkish study, 63.4% patients had axillary lymph 
nodes involved[19] suggesting that the Asian population 
had a propensity to involvement of lymph nodes. Leyrer 
et al. reported 35% rate of distant metastasis;[20] our study 
reported 24.32%.
The surgical approach has been comparative to patients 
with IDC, with breast conserving therapy showing similar 
overall survival to mastectomy in the appropriate patients.[24] 
Table 4: Overall survival according to independent 
variables
Number at risk Overall Survival (%)
Age
<50 9 88.9
>50 30 76.7
Her 2
Positive 7 78.1
Negative 32 78.1
Stage
Stage I 3 66.7
Stage II 23 87
Stage III 10 70
Stage IV 3 66.7
Tumor size
T1 (<2 cm) 3 66.7
T2 (>2-5) 27 88.9
T3 (>5) 7 42.9
T4 2 100
ER*
Positive 18 83.3
Negative 20 75
PR~
Positive 14 92.2
Negative 24 70.8
*ER=Estrogen Receptor, ~PR=Progesterone Receptor
Table 3: Palliative treatment modalities and survival outcomes
Tumor histology Palliative treatment Overall survival (months)
Squamous Cisplatin and Gemcitabine 22
Squamous Temozolomide 15
Squamous Anthracycline and cyclophosphamide--> Paclitaxel and transtuzumab 
--> Vinorelbine and transtuzumab --> Vinorelbine and lapatinib --> 
Lapatinib and Capecitabine -->Everolimus and Exemestane
22
Spindle cell Docetaxel and Cyclophosphamide 14
Spindle cell Paclitaxel --> Capecitabine 21
Spindle cell Exemestane 18
Carcinosarcoma Docetaxel 30
Figure 1: (a) Overall survival of Metaplastic breast cancer patients. (b) Progression‑Free Survival of Metaplastic breast cancer patients
ba
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About 64.3% of our patients underwent modified radical 
mastectomy bearing in mind that 90% patients had a tumor 
size of more than 2 cm.
Standard chemotherapy regimens used for patients with 
IDC have little effect in women with MBC.[25] In a study 
by Rayson et al. 9 patients received adjuvant chemotherapy, 
among which 7 developed disease recurrence (77.7%).[12] 
In our series 19 patients received adjuvant chemotherapy 
and one developed disease recurrence (5.2%). We report 
70% (50% PCR, 20% PR) response to neoadjuvant 
chemotherapy which is way higher than data reported in 
the past. In a study from Cleveland, 39% patients had a 
pCR.[20] In a Turkish study, none of the patients had a 
pCR, and 6.2% partial response.[26] Outcomes are better 
in patients who achieve pCR. In our study none of the 
patients with pCR developed metastatic disease versus 
60% (3/5) in those without pCR. The percentage of 
metastatic disease was 11% vs. 50% in those with and 
without pCR in a similar study.[20]
Historically majority (71%) of MBC cases are triple 
negative.[11,22] Hence, hormonal therapy largely has no role 
in these patients.[10] In our series a total of 38.1% patients 
were found to have triple negative disease. In a study 
by Gultekin et al.[22] none of the patients were her 2-neu 
receptor positive; however, 9.4% of our patients were 
Her-2 neu receptor positive. Estrogen and progesterone 
receptor positivity has been reported up to11.3% and 10.4% 
respectively by Pezzi et al.[1] In our patients 45.2% were ER 
and PR receptor positive. Bae et al. report giving hormonal 
treatment to three patients, with no recurrence in the 
follow up period.[10] Rayson et al. gave palliative tamoxifen 
to 4 patients, but none of them reported any response.[12] 
Thirteen patients received adjuvant hormonal treatment 
among which one patient developed progressive disease. 
Only one patient in this study received palliative hormonal 
treatment and did not have progression till 18 months of 
follow up. She however was lost to follow up later.
The five-year PFS from International data is reported 
between 30% and 69%.[23,27,28] We report a five-year PFS 
of 79.5%. Similarly, various studies report five-year OS 
between 65% and 69%.[20,23,27,28] In our study the five-year 
OS was 76.3%. Both the PFS and OS of our patient 
population are higher than survivals reported from the West. 
However, the higher survival is similar to that reported from 
three Asian countries, namely of patients reported from 
Turkey by Gultekin et al. (76% and 80% five-year PFS and 
OS, respectively), from China by Zhang et al. (67.9% and 
78.7% five-year PFS and OS, respectively) and from Korea 
by Bae et al. (78.1% three-year PFS).[10,11,22] Comparison of 
previous literature in terms of PFS and OS of MBC patients 
with our study is given in Table 6.
MBC is associated with high potential of metastatic disease 
with lungs being the most common site involved.[12,19] In 
our study nine (9/42; 21.42%) patients developed metastatic 
disease, out of which six had lung involved. The median 
overall survival after disease progression was 21 months 
which is higher in comparison to previous study.[12]
In a study by Rayson et al. women younger than 60 years 
and with prior history of estrogen use were associated 
with decreased disease-free survival.[12] In contrast, women 
younger than 50 had better survival in our series. Negative 
nodal involvement was associated with better outcomes in 
a study reported by Dave et al.[24]. No such association was 
found in our study. In a study by Leyrer et al., there was 
no difference in outcomes based on histologic subtype.[20] 
Squamous cell histology was the most common subtype 
in our series. However, outcome analysis could not be 
performed comparing various subtypes as the proportion of 
these was very small.
Unanswered questions and future directions for research
Multiple studies prove that MBC is said to have the worst 
prognosis among all cancer subtypes. There have been case 
reports of use of doxorubicin, ifosfamide, and etoposide 
in sarcomatoid and carcinosarcoma variant of MBC.[29,30] 
However, clinical trials are required to explore these 
potential new therapies.
Strengths of study
To the best of our knowledge, this is the first single 
center study reported at a tertiary care hospital from our 
Table 5: Adjusted analysis of Metaplastic breast 
cancer patient’s survival
Characteristics Overall Survival 
Analysis
Progression-Free 
Survival Analysis
HR* 95% CI¤ P HR* 95% CI¤ P
Her2 Neu 1.8 0.22-15.14 0.6 1.6 0.197-13.04 0.7
Tumor size 1.5 0.54-39.14 0.5 1.9 0.57-6.5 0.3
Stage 1.46 0.62-3.49 0.4 1.4 0.548-3.46 0.5
Nodal Stage 1.54 0.83-2.89 0.2 1.3 0.64-2.78 0.4
Grade 0.3025 0.06-1.61 0.2 0.4 0.044-2.95 0.3
Menupause 0.8175 0.17-3.94 0.8 1.0 0.199-4.91 1.0
Progesterone receptor 4.68 0.58-38.18 0.1 4.6 0.56-37.21 0.2
*HR=Hazard Ratio, ¤CI=Confidence Interval
Table 6: Comparison of previous literature in terms of five-year progression-free and overall survival of MBC 
patients
Author Country Year of publication Number of cases Progression-Free Survival Overall Survival
Fayaz D et al. Kuwait 2017 31 50%¤ 69%
Zein E et al. USA 2017 46 30%¤ 65.30%
Leyrer B et al. USA 2017 113  * 69%
Esbah et al. Turkey 2012 14 33%§ 56%§
Cimino-Mathews et al. USA 2016 45 64% 69%
Samoon et al. Pakistan 2018 42 79.50% 76.30%
*Progression-Free Survival unreported by Authors. ¤Five-year Disease-Free Survival. §Three-year Survival
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region. We report 70% (50% PCR, 20% PR) response to 
neoadjuvant chemotherapy, which is way higher than the 
data reported in the past.
Limitations of study
There were several limitations of the study. This was a 
retrospective study with a small sample. Some patients were 
lost to follow up and data regarding their treatment was 
not available.
Conclusion
In conclusion, MBC is a rare and aggressive variant of 
breast cancer. Five-year progression-free and overall survival 
was 79.5% and 76.3%, respectively. We report better 
survival outcomes when compared to series described earlier 
despite our patient population presenting mostly with high 
grade, large tumors, and half of them exhibiting nodal 
and hormonal involvement. Literature exploring molecular 
targets and clinical trial exploring tumor-specific therapies is 
required to improve disease prognosis.
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